Related Experiment Video
Updated: Jul 12, 2026
08:02
Thin Film Composite Silicon Elastomers for Cell Culture and Skin Applications: Manufacturing and Characterization
Published on: July 3, 2018
Controlled release in transdermal pressure sensitive adhesives using organosilicate nanocomposites
Sohel Shaikh1, Anil Birdi, Syed Qutubuddin
1Department of Chemical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-7217, USA.
Annals of Biomedical Engineering
|September 6, 2007
Summary
Polydimethyl siloxane (PDMS) pressure sensitive adhesives (PSA) were enhanced with organo-clays. This improved drug release control and adhesive properties for transdermal formulations.
Area of Science:
- Materials Science
- Polymer Science
- Nanotechnology
Background:
- Polydimethyl siloxane (PDMS) is a versatile polymer used in various applications.
- Pressure sensitive adhesives (PSA) require specific mechanical and release properties for transdermal drug delivery.
- Organo-clays offer potential for enhancing polymer matrix properties.
Purpose of the Study:
- To fabricate PDMS-based PSA nanocomposites incorporating organo-clays.
- To investigate the effect of organo-clays on drug release kinetics.
- To evaluate the impact of organo-clays on the adhesive properties of PDMS-based PSA.
Main Methods:
- Solution casting of PDMS with varying organo-clay loadings.
- Characterization using X-ray diffraction (XRD) and atomic force microscopy (AFM).
- Drug release studies and mechanical testing (shear strength, SAFT).
Main Results:
- Partially exfoliated PDMS/organo-clay nanocomposites were successfully prepared.
- Organo-clay incorporation significantly reduced initial burst drug release and controlled release kinetics.
- Shear strength increased by over 200%, and SAFT improved by approximately 21%.
Conclusions:
- Optimizing organosilicate additive levels in PDMS enhances transdermal PSA formulations.
- Nanocomposite approach offers superior control over drug release and improved adhesive performance.
- PDMS/organo-clay nanocomposites show promise for advanced transdermal drug delivery systems.
Related Concept Videos
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...